Trump Tariffs Are Already Stunting World Growth
The US and European Union on Sunday agreed a deal that'll see the bloc face 15% tariffs on most of its exports, including automobiles — a level European Commission President Ursula von der Leyen said was the ' best we could get.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Debenhams to fast-track AI capability across business with new programme
This initiative from Debenhams, developed in partnership with workforce development platform Multiverse, aims to bridge the AI skills gap within its workforce The AI Skills Academy is fully funded through Debenhams Group's £1.35m ($1.79m) Apprenticeship Levy, a UK government-backed fund designed to support work-based learning initiatives. The programme is structured to offer on-the-job learning that contributes directly to the company's operations, said Debenhams. Employees participating in the academy will learn to use AI tools to enhance productivity and engage in more strategic work. Debenhams staff will also be trained to apply AI solutions for streamlining operations and reducing manual tasks. They will also learn building in-house AI systems to expedite the digital transition and decrease dependence on external providers. The new initiative aligns with Debenhams Group's digital transformation roadmap, which emphasises 'innovation and continuous learning'. The programme will be introduced to staff through a comprehensive internal communication campaign, featuring in-person sessions led by Multiverse professionals, said the company. Debenhams Group CEO Dan Finley said: 'Adopting AI is not just about investing in our systems – it's about investing in our people. With the launch of the AI Skills Academy, we're giving our teams the tools to think differently, work smarter and build for the future. This is about unlocking the potential of every colleague to drive real innovation across the Group.' The group offers fashion, home, and beauty products through its various retail brands, including Debenhams, Karen Millen, boohoo, boohooMAN, and PrettyLittleThing. Last month, the company entered into a multi-year partnership with Amazon Web Services (AWS) to leverage AI-driven tools for optimising operations and facilitating the scaling of new brands. A recent research from Pusan National University highlighted the potential for generative AI models like ChatGPT and DALL-E 3 to revolutionise fashion design processes and trend identification within the industry. In June, Debenhams Group engaged Peak to overhaul its pricing and promotions approach, implementing an AI-powered system for setting prices on a vast array of products spanning numerous brands. "Debenhams to fast-track AI capability across business with new programme" was originally created and published by Just Style, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Coinbase premium just dropped a huge signal for Bitcoin's price to hit $130,000
US investors are quietly piling into Bitcoin after a wobble that saw its price decline 4% in the last week amid a $9 billion selloff and late-month geopolitical jitters. The bubbling buying spree is visible in the Coinbase Bitcoin premium gap on CryptoQuant, a market data platform. The metric tracks the difference in the Bitcoin price on Coinbase Pro and other exchanges, including Binance. It has flipped positive, signalling that US demand is rebounding, further fuelling analysts' bullishness on Bitcoin's long-term price prospects. 'Bitcoin to trade between $130,000 and $150,000 by year-end, assuming continued [exchange-traded fund] inflows and a stable macro environment, [but] much will hinge on upcoming Federal Reserve decisions, particularly the anticipated rate cut in September,' analysts at TeraHash, a Bitcoin yield protocol, told DL News. An interest rate slash by the Federal Reserve is seen as rocket fuel for Bitcoin because lower interest rate environments favour assets like crypto and stocks. And traders are already pricing in an 88% chance of a September rate cut, according to the CME's FedWatch tool. James Butterfill, head of research at CoinShares, a crypto investment firm, said he expects the Federal Reserve to pivot sharply dovish, a policy shift that favours growth over inflation control, usually by reducing interest rates for cheaper borrowing. 'The Fed is on the back foot and overly concerned with transitory inflation issues and is likely to do a knee-jerk rate cut; it's debatable as to whether this will be September or later, though,' Butterfill said. To be sure, some analysts say Bitcoin has lost some momentum in the short term following its recent price slump. Analysts at Bitfinex, a crypto exchange, say they expect Bitcoin to consolidate between $114,000 and $116,000 unless something triggers new market moves. Bitcoin traded just above $114,000 on Tuesday, down 7% from its all-time high of $122,838 achieved on July 14. Crypto market movers Bitcoin has gained 0.4% over the past 24 hours and is trading at $114,747. Ethereum is up 3.1% in the same period to $3,671. What we're reading Aave's $4.7bn Ethena exposure risks setting off 'liquidity crunch,' adviser says — DL News CurveDAO Member Proposes Cutting L2 Deployments — Unchained Can PumpFun be dethroned? — Milk Road Crypto Donors Sent $45 Million to Trump's Super PAC: Report — Unchained Why Mode Network's investor deposits dropped 99% in one year — DL News Osato Avan-Nomayo is our Nigeria-based DeFi correspondent. He covers DeFi and tech. Got a tip? Please contact him at osato@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
